• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

153.76 +1.03 (+0.67%)
Official Closing Price Updated: 7:00 PM EDT, Jul 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,592,818
Open 153.97
Bid (Size) 151.17 (100)
Ask (Size) 155.73 (100)
Prev. Close 152.73
Today's Range 153.13 - 155.30
52wk Range 112.34 - 170.46
Shares Outstanding N/A
Dividend Yield 3.10%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval ↗
July 17, 2026
Novartis wins traditional FDA approval for Fabhalta, a first-in-class oral treatment slowing kidney decline in adult IgAN. 
Via Benzinga
News headline image
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data
July 14, 2026
New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease... 
Via Newsfile

Performance

YTD
+11.0%
+11.0%
1 Month
+4.5%
+4.5%
3 Month
+1.8%
+1.8%
6 Month
+7.1%
+7.1%
1 Year
+34.6%
+34.6%

More News

Read More
News headline image
Global Nitrogen-Containing Bisphosphonate Drugs Market Growing at 3.1% CAGR Through 2032 ↗
July 14, 2026
Via Talk Markets
News headline image
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗
July 09, 2026
Via The Motley Fool
NOVARTIS AG-SPONSORED ADR (NYSE:NVS): High-Quality Dividend Stock With Strong Profitability and Sustainable Payout ↗
July 07, 2026
Via Chartmill
News headline image
What Is the Vanguard International Dividend Appreciation ETF (VIGI), and Who Should Buy It? ↗
July 09, 2026
Via The Motley Fool
Topics ETFs Economy
News headline image
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up? ↗
July 09, 2026
Via The Motley Fool
Topics ETFs
News headline image
VYMI vs. VIGI: Which International Dividend ETF Is Better? ↗
July 09, 2026
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗
July 08, 2026
Via The Motley Fool
News headline image
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger ↗
July 08, 2026
Via MarketBeat
Topics Artificial Intelligence ETFs Stocks
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition
July 06, 2026
Via Investor Brand Network
News headline image
Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push ↗
July 06, 2026
Via Benzinga
News headline image
Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP? ↗
July 04, 2026
Via The Motley Fool
Topics ETFs
News headline image
New Research Says: The Biggest Gains of AI Won't Go to AI Stocks. These 2 ETFs Could Be Better Buys. ↗
July 04, 2026
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
IEFA vs. VXUS: Both Are Cheap. Both Are Broad. Here Is the Key Difference Long-Term Investors Need to Understand. ↗
July 02, 2026
Via The Motley Fool
Topics ETFs
News headline image
3 European Stocks to Carry Investors Through the Back Half of 2026 ↗
July 01, 2026
Via MarketBeat
Topics ETFs Stocks
News headline image
Core Restore Founder Ann Peets Announces Bladder Leak Treatments In Charleston
June 29, 2026
Via Press Release Distribution Service
News headline image
Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗
June 29, 2026
Via The Motley Fool
News headline image
Novartis, Antares Partner To Pursue Undruggable Cancer Targets In $1.9 Billion Deal ↗
June 24, 2026
Via Benzinga
The Quest to Repair What Multiple Sclerosis Takes Away
June 24, 2026
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
June 24, 2026
Via Investor Brand Network
News headline image
The Quest to Repair What Multiple Sclerosis Takes Away
June 24, 2026
From BioMedWire
Via GlobeNewswire
News headline image
Why I Think This Vanguard ETF Will Beat the S&P 500 Over the Next 10 Years ↗
June 20, 2026
Via The Motley Fool
Topics ETFs Stocks
News headline image
Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain? ↗
June 19, 2026
Via The Motley Fool
News headline image
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study ↗
June 11, 2026
Via Benzinga

Frequently Asked Questions

Is Novartis AG Common Stock publicly traded?
Yes, Novartis AG Common Stock is publicly traded.
What exchange does Novartis AG Common Stock trade on?
Novartis AG Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novartis AG Common Stock?
The ticker symbol for Novartis AG Common Stock is NVS on the New York Stock Exchange
What is the current price of Novartis AG Common Stock?
The current price of Novartis AG Common Stock is 153.76
When was Novartis AG Common Stock last traded?
The last trade of Novartis AG Common Stock was at 07/17/26 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap